A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted locally. The aim of this trial is assess the efficacy and a favorable
benefit-risk ratio for nintedanib in the treatment of LAM at the dose of 150 mg bid